DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Not Applicable

Terminated

Conditions: Obesity
Psoriasis
Hyperlipidemia
Hypertension
Metabolic Syndrome

Interventions: Drug: Etanercept

First Posted Date: 2007-05-22

Last Posted Date: 2016-05-16

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 18

Registration Number: NCT00477191

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Colorectal Cancer Screening Navigator Program for Low Income and Non-English Speaking Populations

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Behavioral: Patient Navigation

First Posted Date: 2007-05-22

Last Posted Date: 2016-09-21

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 1223

Registration Number: NCT00476970

Locations: 🇺🇸
MGH Chelsea Health Center, Chelsea, Massachusetts, United States

DNA Analysis of Blood and Tissue from Patients with Lung Cancer

Recruiting

Conditions: Lung Cancer

First Posted Date: 2007-05-10

Last Posted Date: 2024-11-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 6800

Registration Number: NCT00471978

Locations: 🇺🇸
Harvard School of Public Health, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

HIV and Cardiovascular Risk

Completed

Conditions: Cardiovascular Disease
HIV Infections

First Posted Date: 2007-04-25

Last Posted Date: 2012-10-31

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 129

Registration Number: NCT00465426

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Brain GABA Levels and Treatment Response in Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Escitalopram

First Posted Date: 2007-04-24

Last Posted Date: 2017-01-04

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 40

Registration Number: NCT00464711

Locations: 🇺🇸
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, United States

Seizure Therapy With Intravenous Levetiracetam and Lorazepam

Phase 2

Withdrawn

Conditions: Seizures

Interventions: Drug: Levetiracetam 1 g IV + Lorazepam 2 mg IV
Drug: Placebo + Lorazepam 3 mg IV

First Posted Date: 2007-04-24

Last Posted Date: 2012-11-01

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00465244

Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases

Not Applicable

Completed

Conditions: Cholangiocarcinoma
Hepatic Metastases
Hepatocellular Cancer

Interventions: Procedure: Proton Beam Radiation

First Posted Date: 2007-04-24

Last Posted Date: 2017-01-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 16

Registration Number: NCT00465023

Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)

Phase 4

Completed

Conditions: Obsessive Compulsive Disorder

Interventions: Drug: Duloxetine

First Posted Date: 2007-04-24

Last Posted Date: 2019-03-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT00464698

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Mammography FastTrack Program in Increasing the Number of Women Undergoing Breast Cancer Screening

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: IT System

First Posted Date: 2007-04-19

Last Posted Date: 2013-05-21

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 6730

Registration Number: NCT00462891

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Lymphoma, Diffuse

Interventions: Drug: GM-CSF
Drug: CHOP
Drug: Rituximab

First Posted Date: 2007-04-04

Last Posted Date: 2018-01-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 3

Registration Number: NCT00455897

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy